Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone and Vasopressin in Post-Resuscitation Syndrome
2020-001620-33Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydrocortisone and vasopressin in post-cardiac arrest syndrome (PCAS) and Hemodynamic failure (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Good neurological outcome at day 30. Started Nov 2020; status: active.
02
Drugs
hydrocortisonevasopressin
03
Conditions
post-cardiac arrest syndrome (PCAS)Hemodynamic failure
Beyond the preview
Go deeper on 2020-001620-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001620-33.